Clinical Trial

Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors

Study acronym: MitoCancer
Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this clinical study is to learn more about the effects of urolithin A (MitoPure®) on the immune system of cancer patients receiving immune checkpoint inhibitor-based therapies. Any effects will be compared with patients who take a placebo instead of urolithin A (MitoPure®).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-01; most recent amendment 2026-01-07.
Status change: Not Yet Recruiting → Recruiting 2026-01-07
Trial Details
NCT Number NCT07161310
Lead Sponsor Goethe University
Collaborators: Amazentis SA, Georg-Speyer-Haus
Conditions Solid Cancer, Non-Small Cell Lung Cancer, Melanoma
Enrollment 45 participants
Start Date 2026-01-02
Primary Completion 2027-01 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-01-08